Podcasts

"Not So Different:" The Community Oncology Perspective on Drug Pricing Proposals and Biosimilars

March 31st 2019

The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.

"Not So Different:" Addressing Misinformation on Biosimilars

March 24th 2019

Podcast

Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. After the petition was filed, The Center for Biosimilars® invited an expert group of stakeholders to discuss misinformation about biosimilars as well as what steps are necessary to root out and address the misinformation.

"Not So Different:" Meet the Nonprofit Taking on Generic Drug Shortages

March 10th 2019

Podcast

In January of last year, several hospital groups, representing approximately 450 US hospitals, revealed plans to form a nonprofit generic drug company in a bold move designed to address generic drug shortages and high prices affecting their hospitals.

"Not So Different:" The Supreme Court and US Biosimilars

February 23rd 2019

Podcast

Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do business. One recent case that impacts on upon the biosimilars market was recently heard before the before the United States Supreme Court, and the outcome of the case will potentially impact drug makers seek patent protection for various aspects of their products.

"Not So Different:" Where Do We Stand With Provider Education on Biosimilars?

February 10th 2019

Podcast

Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosimilars® is speaking with Sonia T. Oskouei, PharmD, one of the authors of the review, about the findings.

"Not So Different:" How Biosimilars Advanced in 2018

January 26th 2019

Podcast

Last year was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care®, the parent publication of The Center for Biosimilars®, interviews senior editor, Kelly Davio, about the key developments in biosimilars last year.

"Not So Different:" What's New in Biosimilar Regulation?

August 19th 2018

Podcast

Welcome to Season 2 of Not So Different, a podcast from The Center for Biosimilars®.

"Not So Different" Episode 10: The Patient Perspective on Biosimilars

June 3rd 2018

Podcast

Recently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high drug costs impact patients with rheumatic diseases, and how biosimilars can be part of the solution. Our podcast this week features a portion of our discussion about biologics, biosimilars, and the patient’s viewpoint.

"Not So Different" Episode 9: Biosimilars and Expanded Access to Cancer Treatment

May 20th 2018

Podcast

This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.

"Not So Different" Episode 8: Medicare and Biosimilars

May 6th 2018

Podcast

This week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a variety of prescription drug and mental health-related issue, with an emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare.